Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

被引：0
|
作者：
Xiaohe Su
Kaifeng Jin
Qiji Guo
Ziyue Xu
Zhaopei Liu
Han Zeng
Yiwei Wang
Yu Zhu
Le Xu
Zewei Wang
Yuan Chang
Jiejie Xu
机构：
[1] Fudan University,NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences
[2] Fudan University,Department of Urology, Zhongshan Hospital
[3] Fudan University Shanghai Cancer Center,Department of Urology
[4] Shanghai Jiao Tong University School of Medicine,Department of Urology, Shanghai Ninth People’s Hospital
[5] Shanghai Jiao Tong University School of Medicine,Department of Urology, Ruijin Hospital
来源：
British Journal of Cancer | 2024年 / 130卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：852 / 860
页数：8
相关论文
共 50 条
  • [11] NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
    Yan, Sen
    Zeng, Han
    Jin, Kaifeng
    Shao, Fei
    Liu, Zhaopei
    Chang, Yuan
    Wang, Yiwei
    Zhu, Yu
    Wang, Zewei
    Xu, Le
    Xu, Jiejie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (05)
  • [12] RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer
    Li, Bingyu
    Jin, Kaifeng
    Liu, Zhaopei
    Su, Xiaohe
    Xu, Ziyue
    Liu, Ge
    Xu, Jingtong
    Chang, Yuan
    Wang, Yiwei
    Zhu, Yu
    Xu, Le
    Wang, Zewei
    Liu, Hailong
    Zhang, Weijuan
    JOURNAL OF IMMUNOTHERAPY, 2025, 48 (01) : 18 - 26
  • [13] PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer
    Polak, Paz
    Fu, Lili
    Foulkes, William D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (09): : 866 - 868
  • [14] Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
    Zhang, Min
    Liu, Kehai
    Wang, Mingfu
    RSC ADVANCES, 2019, 9 (58) : 33903 - 33911
  • [15] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [16] PD-1/PD-L1 blockade in renal cell cancer
    Beckermann, Kathryn E.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84
  • [17] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [18] Blood-based biomarker analysis in high PD-L1 expressing NSCLC treated with PD-1/PD-L1 based therapy with or without the addition of platinum-based chemotherapy.
    Fidler, Mary J.
    Villaflor, Victoria Meucci
    Rao, Amol
    Halmos, Balazs
    Bertino, Erin Marie
    Osarogiagbon, Raymond U.
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [19] Toxicities Associated With PD-1/PD-L1 Blockade
    Wang, Daniel Y.
    Johnson, Douglas B.
    Davis, Elizabeth J.
    CANCER JOURNAL, 2018, 24 (01): : 36 - 40
  • [20] PD-1 and PD-L1 blockade in gastrointestinal malignancies
    Lote, Hazel
    Cafferkey, Catherine
    Chau, Ian
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 893 - 903
12345